W
The Wall Street Journal News source @wsj.com · New York City 🇺🇸· Mar 20 ·

#Novartis #Pharmaceuticals #Oncology

Link Preview
www.wsj.com
Novartis to Buy Breast-Cancer Drug From Synnovation for Up to $3 Billion
Novartis is paying $2 billion upfront and up to $1 billion subject to targets to acquire Pikavation Therapeutics. fabrice coffrini/Agence France-Presse/Getty Images Novartis NOVN -1.
Avatar
Morningstar News source @morningstar.com · United States 🇺🇸· Mar 20 ·

#Novartis #oncology #breastcancer

Link Preview
www.morningstar.com
Novartis to Buy Breast-Cancer Drug From Synnovation for Up to $3 Billion -- Update
Novartis struck a deal valued at up to $3 billion to buy an experimental breast-cancer drug from Synnovation Therapeutics, moving to bolster its oncology pipeline with a new treatment approach.
Avatar
Benzinga News source @benzinga.com · Detroit 🇺🇸· Jan 5 ·

#Oncology #Healthcare #BoardOfDirectors

Link Preview
www.benzinga.com
The Oncology Institute Announces Addition of Board Member Mark Stolper - RadNet (NASDAQ:RDNT), Oncology Institute (NASDAQ:TOI)
CERRITOS, Calif.
Avatar
Benzinga News source @benzinga.com · Detroit 🇺🇸· Jan 5 ·

#Pharmaceuticals #Oncology #HealthcareConference

Link Preview
www.benzinga.com
Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - Corbus Pharmaceuticals (NASDAQ:CRBP)
NORWOOD, Mass.
Avatar
NASDAQ Stock Market News source @nasdaq.com · New York City 🇺🇸· Jan 5 ·

#ArtificialIntelligence #DrugDiscovery #Oncology

Link Preview
www.nasdaq.com
InSilico Signs US$888Mln Multi-Year Oncology Drug Discovery Deal With Servier
(RTTNews) - InSilico Medicine Cayman TopCo.
Avatar
Benzinga News source @benzinga.com · Detroit 🇺🇸· Jan 5 ·

#AI #Oncology #Pharmaceuticals

Link Preview
www.benzinga.com
Insilico Medicine Announce US$888 Million Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity NewsletterInsilico Medicine achieved an R&D collaboration with Servier valued at up to US$888 million, focused on discovering and developing innovative oncology therapies, by combining Insilico's AI-driven drug discovery platforms with Servier's global expertise in cancer drug development.
Avatar
NASDAQ Stock Market News source @nasdaq.com · New York City 🇺🇸· Jan 5 ·

#Oncology #DrugDiscovery #AI

Link Preview
www.nasdaq.com
Insilico Medicine Announces US$888 Mln Multi-Year Oncology Collaboration With Servier
(RTTNews) - Insilico Medicine announced that it has entered into a multi-year research and development (R&D) collaboration with Servier, an independent international pharmaceutical company governed by a foundation.
Avatar
NASDAQ Stock Market News source @nasdaq.com · New York City 🇺🇸· Jan 2 ·

#Pfizer #Oncology #Investing

Link Preview
www.nasdaq.com
2 Predictions for Pfizer in 2026
It might take a while longer, but Pfizer is on the path to recovery.